Global Radiopharmaceutical Synthesizer Market – Generate Massive Revenue in Upcoming Future 2021–2031 | Mercurius Health, IBA, Elysia, IAEA


Radiopharmaceutical synthesizers make pharmaceutical products which contain small amounts of radioisotopes by irradiating a specific target which are found inside a nuclear research reactor or in a particle accelerator. Once these radioisotopes are produced, they are tagged on certain molecules based on biological capabilities which result in radiopharmaceuticals.

As with any medical or pharmaceutical product, radiopharmaceuticals are required be produced under carefully controlled conditions and are subject to stringent tests for their quality before they are made commercially available. More than 100 radiopharmaceuticals have been developed, using radioisotopes which were either produced through nuclear reactors or particle accelerators. Radiopharmaceuticals are used to diagnose various medical problems like cardiac anomalies or neurological conditions and are also used to treat certain conditions such as cancers.

For detailed insights on enhancing your product footprint, request for a sample here –

In 2018, the United States FDA and nuclear regulatory authority took steps in order to ensure the supply of a critical radioisotope which is used as an image tracer to detect life threatening diseases. The FDA approved NorthStar Medical Radioisotopes’ RadioGenix system, which is a unique system used for producing molybdenum-99 (Mo-99), a medical radioisotope.

Radiopharmaceutical Synthesizer Market: Drivers and Restraints

Primary factors driving Radiopharmaceutical Synthesizer Market include growing need for safe and effective guiding technology during diagnosis and prognosis of various medical anomalies. Besides, need for accurate procedures to diagnose cardiac neurological and cancerous diseases the discovery of new radiopharmaceuticals have attributed to growth in demand for radiopharmaceutical synthesizers across all end users. Other than the increasing incidences of various anomalies, increasing awareness amongst masses and an expanding application segment are driving the growth of the radiopharmaceutical synthesizer market. However, unawareness towards the procedure in some developing countries is the factor limiting the growth of the global Radiopharmaceutical Synthesizer Market.

To receive extensive list of important regions, ask for TOC here –

Radiopharmaceutical Synthesizer Market: Segmentation

Tentatively, the global Radiopharmaceutical Synthesizer Market has been segmented on the basis of production type, indication, end users, and geography.

Based on indications, the global Radiopharmaceutical Synthesizer Market is segmented as:

  • Cyclotron
  • Nuclear Reactor
  • Radionuclide generator

Based on indications, the global Radiopharmaceutical Synthesizer Market is segmented as:

  • Cancer Treatment
  • Neurology
  • Cardiology

Based on end user, the global Radiopharmaceutical Synthesizer Market is segmented as:

  • Hospitals
  • Pharmaceutical Companies
  • Academic and Research centers

Pre-Book Right Now for Exclusive Analyst Support –

Radiopharmaceutical Synthesizer Market: Key Players

Examples of some of the major players in the global Radiopharmaceutical Synthesizer Market are Mercurius Health, IBA, Elysia, IAEA, Advion, Inc, Advanced Cyclotron Systems, JSC Isotope, Lantheus Medical Imaging, Inc., BV Cyclotron VU, LabLogic Systems Ltd, NorthStar Medical Technologies Technological advancement in already marketed products is the major trend emerging in the global Radiopharmaceutical Synthesizer Market.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website:

Matched content

Editor’s pick

Express Press Release Distribution